Company profile
Lifecore Biomedical, Inc.
NASDAQ: LFCR · Healthcare · Drug Manufacturers - Specialty & Generic
#382 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
66BFH 58DQ 79GM 55SS 79
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), listing tenure · ↓ growth stability, balance-sheet leverage
Methodology →Revenue TTM
$118.9M
Rev growth YoY (TTM)
-19.2%
Net income (FY)
-$18.0M
Employees
382
as of 2026-08-14
Market cap
$177.4M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$75.5M$75.5M2025
Net income-$18.0M-$18.0M2025
Operating income-$733.0k-$733.0k2025
Total assets$232.2M$232.2M2025
Liabilities$198.1M$198.1M2025
Equity-$14.2M-$14.2M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY23
FY24
FY25
FY25
FY25
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Lifecore Biomedical, Inc.’s revenue?
Lifecore Biomedical, Inc. booked $75.5M in FY2025 revenue, growing 772% year over year — faster than 96% of Healthcare companies we track, at a -23.8% net margin.
Peers · Healthcare
Cannara Biotech Inc.76B+CytomX Therapeutics, Inc.63CInterpharm Holdings, Inc.——AbCellera Biologics Inc.54DRecursion Pharmaceuticals, Inc.54DHealwell AI Inc.60CNeighbors
Carver →Key facts
CEOPaul Josephs
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersChaska, MN
ExchangeNASDAQ: LFCR
Employees382
IPO date1996-02-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.